Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Biotech

AstraZeneca Acquires EsoBiotec for $1 Billion to Strengthen Cell-Therapy Portfolio

by Team Lumida
March 17, 2025
in Biotech, Markets
Reading Time: 3 mins read
A A
0
vitamin b 12 100 mg

Photo by Mika Baumeister on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • AstraZeneca will pay $425 million upfront, with an additional $575 million tied to milestones.
  • The acquisition includes EsoBiotec’s innovative in vivo cell therapy platform.
  • The deal is expected to close in Q2 2025 and will not impact AstraZeneca’s 2025 financial guidance.
  • This move positions AstraZeneca to expand its presence in the growing cell-therapy market.

What Happened?

AstraZeneca announced the acquisition of Belgian biotech company EsoBiotec in a deal valued at up to $1 billion. The British pharmaceutical giant will pay $425 million upon closing, expected in the second quarter of 2025, and up to $575 million in milestone payments. The acquisition includes EsoBiotec’s in vivo cell therapy platform, which modifies immune cells directly within the patient’s body, potentially improving accessibility and reducing treatment costs.

Why It Matters?

This acquisition underscores AstraZeneca’s strategic focus on expanding its cell-therapy portfolio, a rapidly growing area in biotechnology. The in vivo cell therapy platform offers a significant advantage by eliminating the need for complex manufacturing processes, which could lower costs and broaden patient access. For investors, this move highlights AstraZeneca’s commitment to innovation and its ability to compete in cutting-edge therapeutic areas, potentially driving long-term growth.

What’s Next?

The deal is expected to close in Q2 2025, with AstraZeneca focusing on integrating EsoBiotec’s technology into its pipeline. Investors should monitor the progress of regulatory approvals and milestone achievements, as these will determine the full financial impact of the acquisition. Additionally, AstraZeneca’s ability to commercialize this platform effectively will be a key factor in its success in the cell-therapy market.

Source
Previous Post

Nvidia Gains on Strong AI Demand Signals from Key Supplier Foxconn

Next Post

China Starts 2025 with Strong Economic Momentum Amid Rising U.S. Tariffs

Recommended For You

S&P 500 and Dow Close in Correction, Nasdaq Drops 5.28% and Erases Its 2026 Gain as the AI Rout Deepens

by Team Lumida
1 day ago

The S&P 500 fell 3.7% into a correction and the Nasdaq dropped 5.28%, turning negative for 2026, in a brutal week for the AI trade.

Read more

Nasdaq 100 Futures Jump 2% and S&P 500 Futures 1.1% as Anthropic’s Above-Range IPO Revives the AI Trade After the S&P 500’s Fifth Straight Loss

by Team Lumida
3 days ago

US stock futures jumped early Thursday as Anthropic’s $83 IPO pricing lifted AI sentiment, after the S&P 500 fell for a fifth straight session.

Read more

Dow Drops 426 Points as Nvidia’s Post-Earnings Bounce Fizzles, With CoreWeave Down 6%, Nebius 4% and Iren 3% as Neoclouds Reverse Early Gains

by Team Lumida
4 days ago

The Dow fell 426 points as Nvidia gave up its post-earnings gains, while CoreWeave, Nebius and Iren reversed early premarket jumps.

Read more

Wall Street Expects Global Earnings Growth to Halve to 16% in 2027 From 33.5%, With Goldman Seeing US Profit Growth Falling From 36% to 11% as AI Capex Growth Peaks in the First Half

by Team Lumida
4 days ago

Analysts expect MSCI ACWI earnings growth to slow to 16% in 2027 from 33.5%, and Goldman sees US profit growth falling to 11% from 36%, the FT reports.

Read more

Dow Falls 760 Points as Chip Stocks Slide Into Nvidia Earnings, With Micron Down 6% and Nvidia on Pace for Its Worst Month Since April 2022

by Team Lumida
5 days ago
BlackRock’s Larry Fink on Economic Growth and Market Misconceptions

The Dow fell 760 points as chipmakers slid ahead of Nvidia earnings, with Micron down about 6% and Nvidia off 26% this month.

Read more

Deutsche Bank Flagged $582 Million of Suspicious Epstein-Linked Payments in US Filings and Once Mistakenly Sent Out Trump’s Tax Statements, Leaked Documents Show

by Team Lumida
5 days ago

Leaked documents show Deutsche Bank filed US suspicious activity reports on $582 million of Epstein-linked transfers and once mistakenly sent Trump’s tax statements.

Read more

S&P 500 Sinks 1.92% and Nasdaq 2.49% for a Third Straight Loss as Nvidia Drops 4.1%, With Futures Mixed Hours Before Its Earnings

by Team Lumida
5 days ago

US stocks fell for a third day as Nvidia slid 4.1%, with the VIX jumping and futures mixed ahead of Nvidia’s results and retail sales data.

Read more

BlackRock Triples Its Equity Overweight to 3% and Broadens AI Bets in Its $300 Billion Model Portfolios, Pulling About $4.4 Billion From Its Treasury ETF

by Team Lumida
6 days ago
Is BlackRock the New Leader in Alternative Investments?

BlackRock lifted its equity overweight to 3% from 1% and broadened AI exposure in its $300 billion model portfolios, driving billions in ETF flows.

Read more

Nasdaq-100 Futures Drop 0.77% and SK Hynix Sinks 5.6% as Markets Brace for Nvidia’s First Post-Huang Earnings and Anthropic’s IPO

by Team Lumida
6 days ago
AI Bulls Trample Bond Market Warnings — S&P 500 Breaks 7,800 as Tech Rally Defies Elevated Yields, Fed Uncertainty, Global Tightening

US stock futures slipped and Asian chipmakers slid as investors braced for Nvidia's earnings and Anthropic's roughly $1.4 trillion IPO.

Read more

Nvidia’s 2031 Bond Yield Rises to 5.717% After Huang’s Exit, With $36 Billion of Neocloud Backstops Now Under Scrutiny

by Team Lumida
1 week ago

Nvidia’s 4.5% bond due 2031 yielded 5.717% on Friday, and analysts are questioning the company’s role in backing AI infrastructure after Jensen Huang’s exit.

Read more
Next Post
China’s Economic Struggles: Factory Activity Falls Again

China Starts 2025 with Strong Economic Momentum Amid Rising U.S. Tariffs

white and brown house near green grass field under white clouds and blue sky during daytime

Selling High-End Homes in Disaster Zones: Real Estate Agents Navigate Challenges Amid Climate Risks

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

ECB’s Panetta Warns AI Valuations Vulnerable to Sharp Market Correction; Highlights Labor Productivity Uncertainty and Inflation Transmission Risks

EV Electricity Use Grows Just 8% as Sales Fall 19% in the Half After Federal Tax Credits Expired

September 30, 2026
Inflation Eases: Will Powell Signal Rate Cuts Soon?

Federal Reserve’s Dilemma: Are Your Investments at Stake?

August 1, 2024
brown and white rope on brown wooden surface

Why Investors Are Going Crazy for Copper: The $43 Billion Battle

May 17, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018